4.7 Review

Intestinal Permeation Enhancers for Oral Delivery of Macromolecules: A Comparison between Salcaprozate Sodium (SNAC) and Sodium Caprate (C10)

Journal

PHARMACEUTICS
Volume 11, Issue 2, Pages -

Publisher

MDPI
DOI: 10.3390/pharmaceutics11020078

Keywords

oral macromolecule delivery; oral peptides; sodium caprate; salcaprozate sodium; epithelial permeability; epithelial transport

Funding

  1. Science Foundation Ireland [13/RC/2073]
  2. CURAM Center for Medical Devices
  3. EU Horizon 2020 Research and Innovation Program under Marie Sklodowska-Curie Grant [666010]
  4. French National Agency of Research and Technology, CIFRE grant [2016/0439]
  5. Sanofi Pharma
  6. Marie Curie Actions (MSCA) [666010] Funding Source: Marie Curie Actions (MSCA)

Ask authors/readers for more resources

Salcaprozate sodium (SNAC) and sodium caprate (C-10) are two of the most advanced intestinal permeation enhancers (PEs) that have been tested in clinical trials for oral delivery of macromolecules. Their effects on intestinal epithelia were studied for over 30 years, yet there is still debate over their mechanisms of action. C-10 acts via openings of epithelial tight junctions and/or membrane perturbation, while for decades SNAC was thought to increase passive transcellular permeation across small intestinal epithelia based on increased lipophilicity arising from non-covalent macromolecule complexation. More recently, an additional mechanism for SNAC associated with a pH-elevating, monomer-inducing, and pepsin-inhibiting effect in the stomach for oral delivery of semaglutide was advocated. Comparing the two surfactants, we found equivocal evidence for discrete mechanisms at the level of epithelial interactions in the small intestine, especially at the high doses used in vivo. Evidence that one agent is more efficacious compared to the other is not convincing, with tablets containing these PEs inducing single-digit highly variable increases in oral bioavailability of payloads in human trials, although this may be adequate for potent macromolecules. Regarding safety, SNAC has generally regarded as safe (GRAS) status and is Food and Drug Administration (FDA)-approved as a medical food (Eligen (R)-Vitamin B-12, Emisphere, Roseland, NJ, USA), whereas C-10 has a long history of use in man, and has food additive status. Evidence for co-absorption of microorganisms in the presence of either SNAC or C-10 has not emerged from clinical trials to date, and long-term effects from repeat dosing beyond six months have yet to be assessed. Since there are no obvious scientific reasons to prefer SNAC over C-10 in orally delivering a poorly permeable macromolecule, then formulation, manufacturing, and commercial considerations are the key drivers in decision-making.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available